Flamingo, a clinical-stage biopharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, has officially started its phase III clínic trial. Here are some of the key details.
Source: streetinsider.comPublished on 2022-08-11
Related news
- Cassava Sciences Reports Full - year 2022 Financial Results and Operating Updates
- Greenwich LifeSciences Provides Year End Update
- Early retirement for Indonesian coal plants could cut CO2 , boost jobs , analysis says
- Smart welcomes new subscribers into the GigaLife with GigaHello freebies
- Greenwich LifeSciences ( GLSI ) Issues Year End Update
- Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial
- Moving to Mastodon ? Here how to select a server for individuals and businesses